Whilst pharmaceutical GLP-1 medications have gained attention for managing type 2 diabetes and obesity, many people are interested in how to naturally stimulate GLP-1 through diet and lifestyle modifications
Additionally, the limited supply of many of these products has increasingly shifted toward use in obesity treatment, driven by profit motives, leaving many type 2 diabetes patients unable to access medications they rely upon
These will focus mainly on medications that are becoming available different ways of using old medications, new formulations, and new drugs in the pipeline
Semaglutide GLP-1 works by targeting multiple pathways in the body, including appetite regulation, calorie intake reduction, and improved metabolic function, which can cause a decrease in the fat in the belly over time
The FDA sent 30 warning letters to telehealth companies in March alone, and by the end of April, they proposed taking semaglutide, tirzepatide, and liraglutide off the 503B Bulk Drug Substances List altogether